Hematology Frontier

With the widespread adoption of chemotherapy-free treatment regimens and breakthroughs in targeted therapies, chronic lymphocytic leukemia (CLL) treatment has entered a new era. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Shenmiao Yang from Peking University People’s Hospital to provide an in-depth analysis of the current state of CLL treatment in China, discuss future research directions, and explore new chapters in the development of the field.

Under the leadership of Dr. Jun Zhu, the Lymphoma Department at Peking Cancer Hospital has become a frontrunner in lymphoma drug development. This year, what innovative achievements from the team will illuminate the treatment path for lymphoma patients? How have they showcased Chinese expertise on the international stage? Additionally, how will the opportunities and challenges China faces in new drug development be transformed into driving forces to enhance lymphoma treatment standards? At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the honor of conducting an in-depth interview with Dr. Jun Zhu. During the discussion, Professor Zhu not only reviewed the illustrious journey of China's lymphoma drug development but also, with his profound insights and forward-looking perspective, envisioned the limitless possibilities in this field's future. Let us delve into Professor Zhu’s remarkable analysis and unique insights on the development of lymphoma drugs in China.

Recently, Professor Xiaofan Zhu, Director of the Division of Pediatric Hematology and Oncology Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Associate Chief Physician Doctor Min Ruan and Attending Doctor LiPeng Liu collaborated on a study titled "Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA," published in Clinical Cancer Research (with an impact factor of 11.5). This prospective study was the first to evaluate the longitudinal changes of ctDNA from plasma in patients, as compared to NGS based bone marrow DNA, for the early detection of relapse in children with AML.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare malignancy of the hematopoietic system, is distinguished by its highly recognizable skin manifestations and complex pathophysiology, which continue to captivate the medical community's investigative spirit and challenge its resolve. Recently, Dr. Yue Lu from Lu Daopei Medical provided an in-depth analysis of BPDCN's origins, clinical presentation, diagnostic methods, and treatment advancements, shedding light on the cutting-edge developments in this field. The following article, based on his insights, has been prepared by Hematology Frontier for our readers.

The breakthrough achievements of CAR-T therapy in the field of hematologic malignancies are remarkable. However, challenges such as target limitations, limited cell sources, and durability of efficacy continue to necessitate further exploration. Dr. Jianxiang Wang's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , stands as a pioneer in the field of immunotherapy, advancing both basic and clinical research to push the boundaries of hematologic cancer immunotherapy. In this issue of Hematology Frontier, Dr. Jianxiang Wang shares the research outcomes and forward-looking insights of his team in the realm of immunotherapy. The aim is to inspire new clinical thinking and collaboratively open a new chapter in hematologic cancer immunotherapy, bringing more hope and possibilities to patients.

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).

In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the hi

On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.